Ken Griffin Pro Qr Therapeutics N.V. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Citadel Advisors LLC holds 3,600 shares of PRQR stock, worth $8,172. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,600

Previous 21,000 82.86%

Holding current value

$8,172

Previous $57,000 92.98%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$1.33 - $2.77 $545,367 - $1.14 Million	410,051 Added 100.3%	818,858 $1.09 Million
Q4 2024 Feb 14, 2025	BUY	$1.81 - $4.49 $582,512 - $1.45 Million	321,830 Added 370.02%	408,807 $1.12 Million
Q3 2024 Nov 14, 2024	BUY	$1.64 - $2.24 $112,523 - $153,690	68,612 Added 373.6%	86,977 $158,000
Q2 2024 Aug 14, 2024	SELL	$1.65 - $2.39 $45,610 - $66,066	-27,643 Reduced 60.08%	18,365 $30,000
Q1 2024 May 15, 2024	SELL	$1.89 - $2.85 $60,117 - $90,652	-31,808 Reduced 40.88%	46,008 $105,000
Q4 2023 Feb 14, 2024	BUY	$1.15 - $2.21 $89,488 - $171,973	77,816 New	77,816 $154,000
Q2 2023 Aug 14, 2023	BUY	$1.62 - $2.32 $27,561 - $39,470	17,013 Added 17.05%	116,792 $189,000
Q1 2023 May 15, 2023	BUY	$1.99 - $3.66 $198,560 - $365,191	99,779 New	99,779 $212,000
Q2 2022 Aug 15, 2022	SELL	$0.56 - $1.0 $7,310 - $13,054	-13,054 Reduced 5.87%	209,215 $162,000
Q4 2021 Feb 14, 2022	BUY	$6.58 - $8.44 $855,814 - $1.1 Million	130,063 Added 141.06%	222,269 $1.78 Million
Q3 2021 Nov 15, 2021	BUY	$5.16 - $8.47 $175,832 - $288,623	34,076 Added 58.62%	92,206 $772,000
Q2 2021 Aug 16, 2021	BUY	$5.75 - $7.59 $171,085 - $225,832	29,754 Added 104.86%	58,130 $391,000
Q1 2021 May 17, 2021	BUY	$4.14 - $9.22 $117,476 - $261,626	28,376 New	28,376 $188,000
Q4 2019 Feb 14, 2020	SELL	$5.84 - $10.51 $385,416 - $693,617	-65,996 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$5.76 - $9.44 $132,312 - $216,846	22,971 Added 53.39%	65,996 $380,000
Q2 2019 Aug 14, 2019	SELL	$9.1 - $15.55 $357,757 - $611,332	-39,314 Reduced 47.75%	43,025 $391,000
Q1 2019 May 15, 2019	BUY	$12.5 - $18.48 $379,587 - $561,182	30,367 Added 58.43%	82,339 $0
Q4 2018 Feb 14, 2019	BUY	$15.25 - $22.4 $792,573 - $1.16 Million	51,972 New	51,972 $820,000

Others Institutions Holding PRQR

# of Institutions

Shares Held

42M

Call Options Held

30.1K

Put Options Held

5.3K

View Full List

About ProQR Therapeutics N.V.

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $162M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

More about PRQR

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account